<!doctype html>
<html lang="en">
<head>
	<meta charset="utf-8" />
	<title>DexTech Medical</title>

	<meta name="viewport" content="width=device-width, initial-scale=1.0" />
	
	<!-- 1140px Grid styles for IE -->
	<!--[if lte IE 9]><link rel="stylesheet" href="css/ie.css" type="text/css" media="screen" /><![endif]-->

	<!-- The 1140px Grid - http://cssgrid.net/ -->
	<link rel="stylesheet" href="css/1140.css" type="text/css" media="screen" />
	
	<!-- TODO: Switch to server-side generated less.. <link rel="stylesheet" href="css/styles.css" type="text/css" media="screen" />-->
    <link rel="stylesheet/less" type="text/css" href="css/elements.less">
    <link rel="stylesheet/less" type="text/css" href="css/styles.less">
    <script src="js/less-1.1.3.min.js" type="text/javascript"></script>
	
	<!--css3-mediaqueries-js - http://code.google.com/p/css3-mediaqueries-js/ - Enables media queries in some unsupported browsers-->
	<script type="text/javascript" src="js/css3-mediaqueries.js"></script>
</head>
<body>
    <header class="container">
        <div class="row">
            <div class="twelvecol last">
                <h1>
                    <img src="img/logo.png" alt="DexTech"/>
                </h1>
                <span>Know-how in Translational Research</span>
            </div>
        </div>
    </header>

    <div class="container clearfix" id="main">
        <div class="row">
            <div class="fourcol">
                <h2>About us</h2>
                <p> DexTech develops drug candidates for urologic oncology, especially prostate cancer, based on glycosylation engineering.</p>
                <p>Close connection between R&amp;D and clinical oncology ensures development of tools for real clinical problems.</p>
                <p>DexTech was established in 2004 by:</p>

                <ul>
                    <li><span class="highlight">Anders Holmberg</span>, a chemical engineer with a PhD in experimental oncology. He is an expert in glycosylation chemistry.</li>
                    <li><span class="highlight">Sten Nilsson (MD, PhD)</span>, a specialist in clinical oncology (urologic oncology, especially prostate cancer).</li>
                </ul>

                <p>Anders Holmberg is managing director and Sten Nilsson is our clinical expert and member of the board.</p>
            </div>

            <div class="eightcol last" id="illustration">
                <img src="/img/illustration.png" alt=""/>
            </div>
        </div>

        <div class="row">
            <div class="fourcol">
                <h2>Partners and Network</h2>
                <h3>Europe</h3>
                <ul>
                    <li>Helsinki University Hospital, Finland</li>
                    <li>European Institute of Oncology, Milan, Italy</li>
                    <li>University of Palermo, Italy</li>
                    <li>University Trás-os-Montes och Alto Douro, Vila Real, Portugal</li>
                </ul>

                <h3>Middle East/Asia</h3>
                <ul>
                    <li>King Feisal Research Center, Ryijad, Saudi Arabia</li>
                    <li>The Weizmann Institute of Science, Israel</li>
                    <li>Shandong University Hospital, Shandong, China</li>
                    <li>Beijing Univ., Beijing, China</li>
                </ul>

                <h3>North America</h3>
                <ul>
                    <li>Sloan Kettering Memorial Cancer Center, New York, USA</li>
                    <li>UANL, Monterrey, Mexico</li>
                    <li>UDEM/Mougerza Hospitals, Monterrey, Mexico</li>
                    <li>TechSphere Corp. Mexico City, Mexico</li>
                </ul>

                <h3>South-America</h3>
                <ul>
                    <li>Ipiranga University Hospital, SauPaulo, Brazil</li>
                </ul>
            </div>

            <div class="fourcol">
                <h2>Contact</h2>
                <address>
                    Visiting Address: <br/>
                    Birger Jarlsgatan 41a, SE-11545 <br/>
                    Stockholm, Sweden.
                </address>

                <p>Telephone: +46. 8. 632.9961 (Mr Kanekrans)</p>

                <address>
                    Postal Address: <br/>
                    Box 119, SE-75104 Uppsala, Sweden<br/>
                    Email: <a href="mailto:arh@telia.com">arh@telia.com</a>
                </address>

                <p>
                    Investor Relations:</br>
                    Mr Peter Kanekrans, (+46.8.632.9961) </br>
                    <a href="mailto:peter@soderlind.se">peter@soderlind.se</a></br>
                </p>
            </div>

            <div class="fourcol last">
                <h2>Drug candidates</h2>
                <p><span class="highlight">CatDex</span>, for instillation therapy of superficial bladder cancer (pre-clinical stage), </p>
                <p><span class="highlight">SomaDex</span>, for palliative treatment of advanced prostate cancer (out licensed, TechSphere Corp., registration phase, Mexico)</p>
                <p><span class="highlight">OsteoDex</span>, for treatment of bone metastasis in advanced prostate cancer (clinical stage, phase1-2a, pending)</p>
                <p>IPR is protected by a family of three world wide applied patents/applications including China and India.</p>
            </div>
        </div>

        <div class="row" id="related_publications">
            <div class="twelvecol last">
                <h2>Selection of Related Publications</h2>
                <ol>
                    <li>Biodistribution, blood half-life and receptor binding of a somatostatin-dextran conjugate. Behe M., Du J., Becker W., Behr T., Angerstein C., Márquez M., Hiltunen J., Nilsson S. and Holmberg A. R. Medical Oncology, 18;1: 59-64, 2001.</li>
                    <li>Development of dextran derivatives with cytotoxic effects in human urinary bladder cancer cell lines. Márquez, M., Du J., Edgren M., Nilsson S., Lennartsson L., Hiltunen J., Westlin J-E., Tammela T., Raitanen M., Laato M. Jönsson G. and Holmberg, A.R. Anticancer Research, 22: 741-744, 2002.</li>
                    <li>A novel somatostatin conjugate with high affinity to all five somatostatin receptor subtypes. U. Wulbrand, M. Feldman, A. Pfestroff, H-C. Fehman, J. Du, J. Hiltunen, M. Marquez, S. Arnold R., Westlin J.E., Nilsson, and A. R. Holmberg. Cancer. 94; 4:1293-1297. Feb 15, 2002.</li>
                    <li>Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer. Joensuu T.K., Nilsson S, Holmberg A.R., Marquez M, Tenhunen M, Saarto T and Jeonsuu H. Ann. N.Y. Acad Sci.1028:361-371, 2004.</li>
                    <li>Charge dependent targeting; results in six tumor cell-lines. M. Márquez, S. Nilsson, L. Lennartsson, Z. Liu, T. Tammela, M. Raitanen, and A. R. Holmberg. AntiCancer Research, 2004.</li>
                    <li>Proteomic analysis of a human prostate cancer cell line alter incubation with a novel Somatostatin 14 derivative. Z. Liu, M. Márquez, S. Nilsson, A.R. Holmberg and A. Alaiya. Cancer Genomics and Proteomics, vol 2, Nov-Dec, 347-352, 2005.</li>
                    <li>Somatostatin effects on the proteome of the LNCaP cell-line. Zhaoxu Liu, Sofia Bengtsson, Morten Krogh, Marcela Marquez, Sten Nilsson, Peter James, Ayodele Aliaya, and Anders R. Holmberg. Int. J. Oncology, 2007.</li>
                    <li>Polymer-conjugated guanidine is a potentially useful anti-tumor agent. Meurling L, Márquez M, Nilsson S and Holmberg AR. Int J Oncol 35: 281-285, 2009.</li>
                    <li>Development of a Novel Poly Bisphosphonate Conjugate for Treatment of Skeletal Metastasis and Osteoporosis. Anders R. Holmberg, Ulf H. Lerner, Ayodele Alyia, Mai Al-Mohanna, Chaker Adra, Marcela Marquez, Lennart Meurling, and Sten Nilsson. Int J Oncology, 37, 563-567, 2010.</li>
                    <li>Application of accelerator mass spectrometry to macromolecules: preclinical pharmacokinetic studies on a polybisphosphonate. Mehran Salehpour, Karl Håkansson, Urban Höglund, Annika Grahn-Westin, Sten Nilsson, Marcela Márquez, Göran Possnert and Anders R. Holmberg. Rapid Commun. Mass Spectrom. 25, 2453–2458, 2011.</li>
                </ol>
            </div>
        </div>
        <div class="breaker"></div>
    </div>

    <footer class="container">
        <div class="row">
            <div class="twelvecol last">
                <span>DexTech Medical AB</span>
                <address>
                    Birger Jarlsgatan 41a,<br/>
                    115 45 Stockholm, Sweden.
                </address>
            </div>
        </div>
    </footer>
</body>
</html>
